Neutropenia in childhood: a 5-year experience at a tertiary center.

Eur J Pediatr

Division of Pediatrics, Department of Clinical Science, Intervention and Technology (CLINTEC), Karolinska Institutet, SE-141 86, Stockholm, Sweden,

Published: June 2015

Unlabelled: Clinical characteristics corroborated by laboratory investigations are essential to determine the etiology in cases of childhood neutropenia and the level of future health-care needs. Here the presentation, findings, and need of interventions in different types of neutropenia in children followed at our center from 2007 to 2012 were investigated retrospectively. Children with congenital and autoimmune neutropenia presented at a significantly younger age and with lower absolute neutrophil granulocyte counts than those with other types of neutropenia (p < 0.01-0.05). The duration of neutropenia, in case of remission, was shorter in post-infection and drug-induced cases compared to autoimmune and chronic idiopathic neutropenias (p = 0.001). Least affected from infections were children with ethnic and post-infection neutropenias compared to the others (p = 0.01-0.05). With the exception of congenital and autoimmune neutropenias, neutropenic children had few clinical infections and few hospital admissions even though the outpatient visit frequency was similar among the groups. A vast majority of the patients received no antibiotic prophylaxis.

Conclusion: The majority of patients with pediatric neutropenia, apart from congenital types, display a benign clinical course. Our data suggest that most neutropenic children need neither antibiotic prophylaxis nor extensive medical attention.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00431-014-2465-5DOI Listing

Publication Analysis

Top Keywords

types neutropenia
8
congenital autoimmune
8
neutropenic children
8
majority patients
8
neutropenia
7
children
5
neutropenia childhood
4
childhood 5-year
4
5-year experience
4
experience tertiary
4

Similar Publications

Purine nucleoside phosphorylase (PNP) deficiency is one of the very rare types of immune deficiency disorders inherited in an autosomal recessive (AR) manner. PNP deficiency is a progressive immune disorder that can range from severe combined immunodeficiency (SCID) to combined immunodeficiency and is associated with recurrent infections, neurological manifestations, and sometimes autoimmune disorders. In our case, we describe the case of a female patient, two years and six months old, with recurrent infections, severe neutropenia, failure to thrive, and a history of a deceased sister with the same condition.

View Article and Find Full Text PDF

Background  Systemic Lupus Erythematosus (SLE) is a multifaceted autoimmune disorder with diverse clinical presentations, among which hematological abnormalities often serve as early and critical indicators of disease. These manifestations, including anemia, leukopenia, lymphopenia, and thrombocytopenia, correlate with disease activity and provide essential diagnostic insights, particularly in resource-limited settings where access to advanced diagnostic tools may be constrained. This study emphasizes the significance of hematological findings that frequently appear at the initial presentation of SLE.

View Article and Find Full Text PDF

Prostate cancer is one of the most frequently diagnosed cancers and poses a significant health burden. New androgen-targeted therapies are now standard treatments for various stages of prostate cancer, including hormone-sensitive, metastatic, and non-metastatic castration-resistant types. These therapies are generally well tolerated and often have fewer side effects compared to traditional chemotherapy.

View Article and Find Full Text PDF

Background: Both novel anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugates (ADCs) and pertuzumab and trastuzumab (HP) combined with chemotherapy(C) regimens are the choice of treatment for HER2 positive metastatic breast cancer (MBC) after tyrosine kinase inhibitors (TKIs). Our team's previous research has shown significant therapeutic effects of novel anti-HER2 ADCs in patients with TKIs treatment failure. Unfortunately, there is currently no data available to compare novel anti-HER2 ADCs with HP combined with chemotherapy regimens.

View Article and Find Full Text PDF

The use of granulocyte colony-stimulating factor (GCSF) to control febrile neutropenia (FN) caused by anti-cancer chemotherapy is well documented but it still needs to evaluated with respect to the specific type of cancer and chemotherapeutic agents. The present study evaluates the efficacy of adjunctive GCSF for treating FN after taking anticancer therapy by measuring clinical, hematological and microbiological outcomes. It is a single center study conducted at Hayatabad Medical Complex (HMC), Peshawar, Pakistan.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!